Rotavirus Vaccine Market to Reach USD 11.46 Billion by 2030 as Global Immunization Programs and Affordable Vaccines Drive Expansion

Rotavirus Vaccine Market Overview and Growth Drivers

The global Rotavirus Vaccine Market is witnessing consistent expansion as governments, healthcare organizations, and vaccine manufacturers strengthen efforts to prevent severe rotavirus infections among infants and young children. According to Maximize Market Research, the global Rotavirus Vaccine Market was valued at USD 7.42 billion in 2023 and is projected to reach approximately USD 11.46 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030. Rising disease burden, increasing childhood vaccination coverage, expansion of national immunization programs, and greater awareness of rotavirus-related complications are key factors supporting market growth. The inclusion of rotavirus vaccines in national immunization programs provides manufacturers with stable demand while improving accessibility among vulnerable populations. Affordable products such as Rotavac are also helping expand vaccination access in developing economies. Additional opportunities are emerging from research into booster doses, improved delivery methods, longer-lasting protection, and multivalent vaccines capable of addressing a wider range of rotavirus strains. However, affordability, vaccine hesitancy, cold-chain requirements, and concerns surrounding duration of protection remain important market challenges.

* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/231929/ 

U.S. Market Trends and Investment in 2025

The United States remains a major market for rotavirus vaccination because of its established healthcare infrastructure, broad insurance coverage, high vaccination awareness, and government-supported childhood immunization programs. MMR identifies the United States as the leading country within North America and highlights the role of the Vaccines for Children (VFC) program in improving access for eligible children. In 2025, vaccine manufacturers continued investing in broader vaccine innovation and manufacturing capabilities. Sanofi reported continued investment in vaccine research and development during 2025 and highlighted the contribution of new vaccine launches to its growth. The company also maintains a large-scale vaccine manufacturing network, with more than €1 billion invested annually across capacity expansion, digital manufacturing, and modernization. Merck also continued to maintain its vaccine manufacturing and supply infrastructure, supporting the broader U.S. vaccine ecosystem. These investments in manufacturing resilience, research, and advanced production technologies can strengthen long-term vaccine availability and support the wider preventive-healthcare market.

Market Segmentation: Rotarix Holds the Largest Share

Based on type, the Rotarix segment held the largest revenue share of the global Rotavirus Vaccine Market in 2022, according to MMR. Rotarix has established strong global recognition since its introduction and has been incorporated into vaccination programs in more than 90 countries, supporting broad distribution and adoption. The vaccine's demonstrated effectiveness in reducing severe rotavirus disease and hospitalizations has strengthened its position among healthcare providers and parents. Continued integration of rotavirus vaccination into public immunization programs is expected to support demand for established vaccine products while encouraging manufacturers to develop improved formulations and delivery approaches.

Key Players in the Rotavirus Vaccine Market
1. Merck & Co., Inc. (US)
2. Bharat Biotech (India)
3. GlaxoSmithKline plc. (UK)
4. Sanofi (France)
5. Lanzhou Institute of Biologicals Products Co. Ltd (China)
6. BIOVIRx Inc (US)
7. Serum Institute of India Pvt.
8. Biological E (India)
9. Pfizer Inc. (US)
10. GlaxoSmithKline plc. (UK)
11. Bio Farma (Indonesia)
12. Novartis AG (Switzerland)
13. Berghofer Medical Research Institute (Australia)
14. Nuvonis
15. Jamanetwork
16. Thelancet
17. Kff
18. Gsk
19. journals

Competitive Analysis

The MMR report identifies Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc., Sanofi, and Lanzhou Institute of Biological Products Co. Ltd among the key players in the global Rotavirus Vaccine Market. The MMR report does not provide individual market-share percentages for these companies, so specific shares have not been assigned.

Merck & Co., Inc. is an important participant through its RotaTeq vaccine and broader vaccine manufacturing capabilities. The company continues to emphasize manufacturing, supply-chain resilience, and vaccine availability, providing a foundation for continued participation in the rotavirus vaccine market.

Bharat Biotech has established an important position through Rotavac, an affordable indigenous oral rotavirus vaccine that has supported expanded immunization in India and other developing markets. The company's focus on cost-effective vaccine manufacturing can create further opportunities in price-sensitive countries. Research published in 2025 also evaluated the real-world impact of Rotavac following its introduction into India's Universal Immunization Programme.

GlaxoSmithKline plc. remains a major vaccine developer through Rotarix and its broader vaccine portfolio. Continued investment in vaccine research, manufacturing, and supply capabilities can support future innovation and global availability.

Sanofi strengthened its broader vaccine innovation strategy during 2025. Its investment in R&D and manufacturing modernization, together with AI-enabled production capabilities, reflects the industry's shift toward more efficient and resilient vaccine manufacturing.

Lanzhou Institute of Biological Products Co. Ltd is an important Chinese participant, particularly through its Lanzhou lamb rotavirus vaccine. China has multiple rotavirus vaccine products in use, and continued development of new formulations and strain coverage can create opportunities for domestic market expansion.

Regional Analysis: United States

The United States holds the largest share within the North American Rotavirus Vaccine Market, according to MMR. The country's strong healthcare infrastructure, insurance coverage, vaccination awareness, and government-supported programs contribute to market leadership. The VFC program provides vaccines at no cost to eligible children, improving access and supporting immunization coverage. MMR also notes that U.S. vaccination campaigns and public awareness initiatives strengthen demand for rotavirus vaccination. Continued investment in vaccine manufacturing, research, supply-chain resilience, and preventive healthcare is expected to reinforce the U.S. position. MMR does not disclose a specific percentage for the U.S. share of the global market, so no country-level percentage has been estimated.

Related Reports

Menstrual Cup Market https://www.maximizemarketresearch.com/market-report/menstrual-cup-market/213519/ 

Global Pharmaceutical Cartridges Market https://www.maximizemarketresearch.com/market-report/global-pharmaceutical-cartridges-market/31646/ 

Prescription Pharmaceuticals Market https://www.maximizemarketresearch.com/market-report/prescription-pharmaceuticals-market/330/ 

Conclusion

The Rotavirus Vaccine Market is positioned for sustained growth as governments expand childhood immunization programs and manufacturers improve affordability, accessibility, and vaccine technology. The market's projected increase from USD 7.42 billion in 2023 to USD 11.46 billion by 2030 reflects the continuing importance of rotavirus prevention.

In our view, the strongest opportunities will arise from expanded national immunization programs, affordable vaccine production, multivalent formulations, improved delivery technologies, longer-lasting protection, and stronger vaccine manufacturing capacity. Increasing vaccination coverage in developing economies represents a particularly important opportunity, while innovation in formulations and production efficiency can help manufacturers address affordability and accessibility challenges. Companies combining strong clinical evidence with scalable manufacturing and global distribution capabilities are likely to benefit most from the market's long-term expansion.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com